Blood cancers

Australian clinical experience shows time on treatment for ibrutinib

Australian real world clinical experience of ibrutinib (Imbruvica) in patients with relapsed or refractory Chronic Lymphocytic Leukemia (CLL) shows that patient duration on therapy matches closely with the phase 3 trial findings. Results from more than 1000 patients who accessed ibrutinib via the Named Patient Program (NPP) between 2014 and 2017 before it was listed on ...

Already a member?

Login to keep reading.

© 2021 the limbic